Brokerages forecast that Unity Biotechnology Inc (NASDAQ:UBX) will announce ($0.44) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Unity Biotechnology’s earnings. Unity Biotechnology posted earnings per share of ($0.69) in the same quarter last year, which would suggest a positive year over year growth rate of 36.2%. The company is scheduled to issue its next earnings report on Thursday, August 8th.

According to Zacks, analysts expect that Unity Biotechnology will report full year earnings of ($1.91) per share for the current financial year, with EPS estimates ranging from ($1.98) to ($1.83). For the next fiscal year, analysts forecast that the business will post earnings of ($2.14) per share, with EPS estimates ranging from ($2.35) to ($1.93). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Unity Biotechnology.

Unity Biotechnology (NASDAQ:UBX) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.03.

Separately, Zacks Investment Research cut shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $22.00.

UBX traded down $0.26 during trading on Thursday, hitting $8.48. The stock had a trading volume of 1,542 shares, compared to its average volume of 216,277. The company has a market capitalization of $375.01 million, a price-to-earnings ratio of -3.35 and a beta of -0.25. The business has a 50-day moving average of $8.58. Unity Biotechnology has a twelve month low of $7.30 and a twelve month high of $24.56.

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA lifted its stake in Unity Biotechnology by 5,850.0% during the first quarter. BNP Paribas Arbitrage SA now owns 5,355 shares of the company’s stock worth $43,000 after purchasing an additional 5,265 shares during the last quarter. Legal & General Group Plc lifted its stake in Unity Biotechnology by 416.4% during the fourth quarter. Legal & General Group Plc now owns 3,863 shares of the company’s stock worth $63,000 after purchasing an additional 3,115 shares during the last quarter. SG Americas Securities LLC bought a new position in Unity Biotechnology during the first quarter worth $105,000. Citigroup Inc. lifted its stake in Unity Biotechnology by 374.7% during the fourth quarter. Citigroup Inc. now owns 6,589 shares of the company’s stock worth $107,000 after purchasing an additional 5,201 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY bought a new stake in Unity Biotechnology in the fourth quarter valued at $144,000. Hedge funds and other institutional investors own 38.21% of the company’s stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

Read More: What is the accumulation/distribution indicator?

Get a free copy of the Zacks research report on Unity Biotechnology (UBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.